Mode
Text Size
Log in / Sign up

Allergy & Immunology

604 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Immune checkpoint inhibitor regimens for colorectal cancer increase risk of endocrine adverse events
Allergy & Immunology Meta-analysis
Immune checkpoint inhibitor regimens for colorectal cancer increase risk of endocrine adverse events Immunotherapy for colon cancer linked to thyroid problems
This network meta-analysis evaluates endocrine toxicity in patients with colorectal cancer treated with immune checkpoint inhibitor (ICI) ba…
New analysis finds immunotherapy for colorectal cancer raises risk of thyroid issues, especially with certain drug combos.
LncRNA signatures predict ICI response and survival across cancers in systematic review
Allergy & Immunology Meta-analysis
LncRNA signatures predict ICI response and survival across cancers in systematic review lncRNA Signatures May Help Predict Response to Cancer Treatment
A systematic review of 31 studies found that lncRNA-based signatures consistently stratify cancer patients into groups with significantly di…
Specific genetic markers called lncRNAs may help doctors predict how well cancer patients will respond to immune checkpoint inhibitor treatm…
Macrophage phenotypic plasticity and metabolism influenced by tissue niches contribute to obesity and metabolic disease
Allergy & Immunology Sys. Review
Macrophage phenotypic plasticity and metabolism influenced by tissue niches contribute to obesity and metabolic disease Macrophage Metabolism in Obesity Offers New Treatment Clues
This narrative review explores how macrophage metabolism and functional phenotypes are shaped by environmental cues and specific tissue nich…
A review reveals how macrophages change their metabolism in different tissues during obesity, pointing to new ways to treat metabolic diseas…
FDA Approves Ryaltris (olopatadine/mometasone) for Seasonal Allergic Rhinitis
Allergy & Immunology FDA Approval
FDA Approves Ryaltris (olopatadine/mometasone) for Seasonal Allergic Rhinitis FDA approves new nasal spray Ryaltris for seasonal allergy symptoms
The FDA approved Ryaltris, a combination of olopatadine (H1-receptor inhibitor) and mometasone furoate (corticosteroid), for seasonal allerg…
The FDA approved Ryaltris, a nasal spray that combines an antihistamine and a corticosteroid, for seasonal allergies in adults and teens 12 …
Neoadjuvant chemoimmunotherapy improves pathological response and surgical rates in resectable esophageal squamous cell carcinoma
Allergy & Immunology Meta-analysis
Neoadjuvant chemoimmunotherapy improves pathological response and surgical rates in resectable esophageal squamous cell carcinoma Immune therapy shows promise for esophageal squamous cell carcinoma
This meta-analysis of randomized controlled trials involving 1070 patients found that neoadjuvant chemoimmunotherapy (NIC) significantly imp…
Adding immune checkpoint inhibitors to chemotherapy before surgery significantly improves tumor response rates in patients with esophageal c…
KRAS G12C inhibitors improve progression-free survival with HR 0.62 in KRASG12C-mutated solid tumors
Allergy & Immunology Meta-analysis
KRAS G12C inhibitors improve progression-free survival with HR 0.62 in KRASG12C-mutated solid tumors New drugs show promise for patients with specific tumor mutations
This meta-analysis of 3 RCTs involving 949 patients evaluated KRAS G12C inhibitors for solid tumors. The analysis found a significant improv…
A new class of drugs shows promise in slowing the growth of certain solid tumors for patients with a specific genetic mutation.
B cell and humoral immunity pathways provide potential targets for modulating inflammation in Inflammatory Bowel Disease
Allergy & Immunology Sys. Review
B cell and humoral immunity pathways provide potential targets for modulating inflammation in Inflammatory Bowel Disease B Cell Therapies Show Potential for Inflammatory Bowel Disease
This systematic review evaluates the B cell-humoral immunity regulatory axis in patients with inflammatory bowel disease (IBD). The authors …
New research highlights how targeting B cells and antibody pathways may help manage inflammation in people with inflammatory bowel disease.
Metabolic reprogramming in the tumor microenvironment drives immune evasion and immunotherapy resistance in gastric cancer
Allergy & Immunology Sys. Review
Metabolic reprogramming in the tumor microenvironment drives immune evasion and immunotherapy resistance in gastric cancer How stomach cancer tricks the immune system to survive
This narrative review explores how metabolic crosstalk and nutrient competition within the tumor microenvironment influence immune suppressi…
Stomach cancer cells starve immune cells of nutrients and flood the area with waste, helping the tumor hide from treatment.
Radiomics and spatial omics offer theoretical framework for precision bladder cancer care
Allergy & Immunology Sys. Review
Radiomics and spatial omics offer theoretical framework for precision bladder cancer care New Imaging and Spatial Data Help Map Bladder Cancer
This systematic review synthesizes evidence on radiomics and spatial omics for characterizing the bladder cancer immune microenvironment. It…
Advanced imaging and spatial mapping offer new ways to study the complex environment around bladder cancer tumors.
Dysregulated m6A methylation contributes to hepatic fibrosis and inflammation in radiation-induced liver injury
Allergy & Immunology Meta-analysis
Dysregulated m6A methylation contributes to hepatic fibrosis and inflammation in radiation-induced liver injury Radiation exposure causes liver damage through changes in RNA
This narrative review explores the role of m6A modification in radiation-induced liver injury (RILI). The authors synthesize evidence that i…
New research shows how radiation alters a specific chemical mark on cells, potentially leading to serious liver injury.
FDA Approves Zyrtec-d 12 Hour (cetirizine/pseudoephedrine) for Allergy Symptoms
Allergy & Immunology FDA Approval
FDA Approves Zyrtec-d 12 Hour (cetirizine/pseudoephedrine) for Allergy Symptoms FDA approves Zyrtec-d 12 Hour for allergy and sinus relief.
FDA approved Zyrtec-d 12 Hour (cetirizine HCl/pseudoephedrine HCl) for temporary relief of hay fever or upper respiratory allergy symptoms i…
The FDA approved Zyrtec-d 12 Hour, a nonprescription tablet that combines an antihistamine and a decongestant. It treats symptoms like runny…
FDA Approves Zyrtec Allergy (cetirizine) for Hay Fever and Upper Respiratory Allergy Symptoms
Allergy & Immunology FDA Approval
FDA Approves Zyrtec Allergy (cetirizine) for Hay Fever and Upper Respiratory Allergy Symptoms FDA approves new melt-in-mouth allergy drug Zyrtec Allergy.
The FDA approved Zyrtec Allergy (cetirizine) 10 mg orally disintegrating tablets for temporary relief of symptoms due to hay fever or other …
The FDA approved Zyrtec Allergy (cetirizine) 10 mg orally disintegrating tablets for hay fever and allergy symptoms. The tablet melts in the…